According to Quotient's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.0358741. At the end of 2022 the company had a P/S ratio of 0.0359.
Year | P/S ratio | Change |
---|---|---|
2022 | 0.0359 | -99.48% |
2021 | 6.91 | -44.35% |
2020 | 12.4 | -47.59% |
2019 | 23.7 | 60.71% |
2018 | 14.7 | 57.58% |
2017 | 9.35 | 42.38% |
2016 | 6.57 | -65.98% |
2015 | 19.3 | 25.05% |
2014 | 15.4 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Atossa Therapeutics ATOS | N/A | N/A | ๐บ๐ธ USA |
Chembio Diagnostics CEMI | 0.3457 | 863.60% | ๐บ๐ธ USA |
Eterna Therapeutics ERNA | 191 | 532,186.52% | ๐บ๐ธ USA |